GSK
GSK
827 hedge funds and large institutions have $9.91B invested in GSK in 2023 Q2 according to their latest regulatory filings, with 81 funds opening new positions, 291 increasing their positions, 275 reducing their positions, and 58 closing their positions.
55% more call options, than puts
Call options by funds: $207M | Put options by funds: $133M
40% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 58
2% more funds holding
Funds holding: 809 → 827 (+18)
6% more repeat investments, than reductions
Existing positions increased: 291 | Existing positions reduced: 275
3% more capital invested
Capital invested by funds: $9.66B → $9.91B (+$246M)
0.13% more ownership
Funds ownership: 6.66% → 6.79% (+0.13%)
15% less funds holding in top 10
Funds holding in top 10: 13 → 11 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$198M |
| 2 |
Primecap Management
Pasadena,
California
|
+$68.2M |
| 3 |
PTC
Provident Trust Company
Waukesha,
Wisconsin
|
+$64.6M |
| 4 |
Morgan Stanley
New York
|
+$64.2M |
| 5 |
Holocene Advisors
New York
|
+$62.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$105M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$94.4M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$56.5M |
| 4 |
Renaissance Technologies
New York
|
-$43.3M |
| 5 |
Goldman Sachs
New York
|
-$36M |
GSK Hedge Fund Activity: Q2 2023 in Review
827 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q2 2023, worth a combined $9.91B — up 2.5% from $9.66B a quarter earlier.
Buyers outnumbered sellers: 81 funds opened new GSK positions and 58 closed out — a net gain of 23 holders — while 291 added to existing stakes and 275 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $198M. The largest seller was Armistice Capital, cutting an estimated $105M.
- 827 institutional investors held GSK (GSK) as of Q2 2023, up from 809 in Q1 2023.
- Funds reported $9.91B of GSK stock for Q2 2023, up 2.5% quarter-over-quarter.
- 81 funds opened new GSK positions in Q2 2023 and 58 closed out, a net change of +23 holders.
- The largest GSK buyer in Q2 2023 was Royal Bank of Canada, an estimated $198M added.
- The largest GSK seller in Q2 2023 was Armistice Capital, an estimated $105M sold.
Based on aggregated 13F filings for Q2 2023.